Literature DB >> 34850039

Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.

Michael J Johnson1, Cuining Liu2, Debashis Ghosh2, Nancy Lang1, Myron J Levin1, Adriana Weinberg1.   

Abstract

We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immune responses; immunogenicity; old adults; recombinant zoster vaccine; zoster vaccine live

Mesh:

Substances:

Year:  2022        PMID: 34850039      PMCID: PMC9016444          DOI: 10.1093/infdis/jiab580

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  15 in total

1.  Long-term persistence of zoster vaccine efficacy.

Authors:  Vicki A Morrison; Gary R Johnson; Kenneth E Schmader; Myron J Levin; Jane H Zhang; David J Looney; Robert Betts; Larry Gelb; John C Guatelli; Ruth Harbecke; Connie Pachucki; Susan Keay; Barbara Menzies; Marie R Griffin; Carol A Kauffman; Adriana Marques; John Toney; Kathy Boardman; Shu-Chih Su; Xiaoming Li; Ivan S F Chan; Janie Parrino; Paula Annunziato; Michael N Oxman
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

2.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

3.  Th1 memory differentiates recombinant from live herpes zoster vaccines.

Authors:  Myron J Levin; Miranda E Kroehl; Michael J Johnson; Andrew Hammes; Dominik Reinhold; Nancy Lang; Adriana Weinberg
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

4.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Authors:  Himal Lal; Anthony L Cunningham; Olivier Godeaux; Roman Chlibek; Javier Diez-Domingo; Shinn-Jang Hwang; Myron J Levin; Janet E McElhaney; Airi Poder; Joan Puig-Barberà; Timo Vesikari; Daisuke Watanabe; Lily Weckx; Toufik Zahaf; Thomas C Heineman
Journal:  N Engl J Med       Date:  2015-04-28       Impact factor: 91.245

Review 5.  VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study.

Authors:  Hideo Asada
Journal:  Vaccine       Date:  2019-09-19       Impact factor: 3.641

6.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

7.  Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts.

Authors:  Randall J Cohrs; Satish K Mehta; D Scott Schmid; Donald H Gilden; Duane L Pierson
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

8.  Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.

Authors:  A Wilson; M Sharp; C M Koropchak; S F Ting; A M Arvin
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

9.  Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Authors:  Anthony L Cunningham; Thomas C Heineman; Himal Lal; Olivier Godeaux; Roman Chlibek; Shinn-Jang Hwang; Janet E McElhaney; Timo Vesikari; Charles Andrews; Won Suk Choi; Meral Esen; Hideyuki Ikematsu; Martina Kovac Choma; Karlis Pauksens; Stéphanie Ravault; Bruno Salaun; Tino F Schwarz; Jan Smetana; Carline Vanden Abeele; Peter Van den Steen; Ilse Vastiau; Lily Yin Weckx; Myron J Levin
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

10.  Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination.

Authors:  Janet J Sei; Kara S Cox; Sheri A Dubey; Joseph M Antonello; David L Krah; Danilo R Casimiro; Kalpit A Vora
Journal:  Front Immunol       Date:  2015-10-29       Impact factor: 7.561

View more
  1 in total

1.  Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.

Authors:  Yue Xia; Xue Zhang; Liuren Zhang; Chuanxi Fu
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.